Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty.

In stent restenosis: bane of the stent era. J Clin Pathol (2006) 1.71

Genetic and genomic insights into the molecular basis of atherosclerosis. Cell Metab (2007) 1.27

CD40 ligand promotes Mac-1 expression, leukocyte recruitment, and neointima formation after vascular injury. Am J Pathol (2008) 1.07

Nuclear factor of activated T cells (NFAT) mediates CD154 expression in megakaryocytes. Blood (2008) 0.96

CD40L deficiency attenuates diet-induced adipose tissue inflammation by impairing immune cell accumulation and production of pathogenic IgG-antibodies. PLoS One (2012) 0.87

PROCLAIM: pilot study to examine the effects of clopidogrel on inflammatory markers in patients with metabolic syndrome receiving low-dose aspirin. Tex Heart Inst J (2009) 0.84

Impact of the CD40-CD40L dyad in Alzheimer's disease. CNS Neurol Disord Drug Targets (2010) 0.82

Premature labor: a state of platelet activation? J Perinat Med (2008) 0.82

Circulating inflammatory cells are associated with vein graft stenosis. J Vasc Surg (2011) 0.81

Biomarkers of chronic inflammatory state in uremia and cardiovascular disease. Int J Inflam (2012) 0.81

Roles of the kinase TAK1 in CD40-mediated effects on vascular oxidative stress and neointima formation after vascular injury. PLoS One (2014) 0.78

Soluble CD40 ligand as a predictor of coronary artery disease and long-term clinical outcomes in stable patients undergoing coronary angiography. Cardiology (2007) 0.77

Developmental changes in soluble CD40 ligand. J Pediatr (2007) 0.76

Soluble CD40 ligand levels in acute pulmonary embolism: a prospective, randomized, controlled study. Heart Vessels (2011) 0.75

Coronary artery disease progression is associated with C-reactive protein and conventional risk factors but not soluble CD40 ligand. Can J Cardiol (2006) 0.75

Soluble CD40 ligand levels in otherwise healthy subjects with impaired fasting glucose. Mediators Inflamm (2006) 0.75

EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol (2005) 5.07

Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension (2006) 4.20

Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens (2005) 4.19

A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol (2006) 3.74

Short-term administration of dark chocolate is followed by a significant increase in insulin sensitivity and a decrease in blood pressure in healthy persons. Am J Clin Nutr (2005) 3.66

Cocoa reduces blood pressure and insulin resistance and improves endothelium-dependent vasodilation in hypertensives. Hypertension (2005) 3.26

(In)accuracy of blood pressure measurement in 14 Italian hospitals. J Hypertens (2012) 2.76

The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation (2003) 2.14

Randomized study of the crush technique versus provisional side-branch stenting in true coronary bifurcations: the CACTUS (Coronary Bifurcations: Application of the Crushing Technique Using Sirolimus-Eluting Stents) Study. Circulation (2008) 2.12

Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens (2005) 2.12

Viscero-visceral hyperalgesia: characterization in different clinical models. Pain (2010) 2.07

Blood pressure is reduced and insulin sensitivity increased in glucose-intolerant, hypertensive subjects after 15 days of consuming high-polyphenol dark chocolate. J Nutr (2008) 1.71

Atorvastatin reduces macrophage accumulation in atherosclerotic plaques: a comparison of a nonstatin-based regimen in patients undergoing carotid endarterectomy. Stroke (2010) 1.67

Prognostic value of different indices of blood pressure variability in hypertensive patients. Am J Hypertens (2009) 1.59

Increased expression of transforming growth factor-beta1 as a stabilizing factor in human atherosclerotic plaques. Stroke (2004) 1.57

Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. Int J Cancer (2006) 1.55

Effects of bezafibrate and simvastatin on endothelial activation and lipid peroxidation in hypercholesterolemia: evidence of different vascular protection by different lipid-lowering treatments. J Clin Endocrinol Metab (2003) 1.54

Risk reduction after regression of echocardiographic left ventricular hypertrophy in hypertension: a meta-analysis. Am J Hypertens (2010) 1.49

Epicardial adipose tissue and metabolic syndrome in hypertensive patients with normal body weight and waist circumference. Am J Hypertens (2011) 1.48

The aldosterone-renin ratio based on the plasma renin activity and the direct renin assay for diagnosing aldosterone-producing adenoma. J Hypertens (2010) 1.46

Regression of echocardiographic left ventricular hypertrophy after 2 years of therapy reduces cardiovascular risk in patients with essential hypertension. Am J Hypertens (2008) 1.45

Resistance training improves skeletal muscle insulin sensitivity in elderly offspring of overweight and obese mothers. Diabetologia (2016) 1.45

Within-patient reproducibility of the aldosterone: renin ratio in primary aldosteronism. Hypertension (2009) 1.45

A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA (2004) 1.40

Soluble CD40 ligand is predictive of combined cardiovascular morbidity and mortality in patients on haemodialysis at a relatively short-term follow-up. Nephrol Dial Transplant (2011) 1.40

Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: an updated meta analysis. Am J Hypertens (2010) 1.39

[Hypertensive heart disease: diagnostic and therapeutic guidelines]. G Ital Cardiol (Rome) (2008) 1.39

Long-term blood pressure changes induced by the 2009 L'Aquila earthquake: assessment by 24 h ambulatory monitoring. Hypertens Res (2013) 1.39

Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J Clin Endocrinol Metab (2008) 1.38

Limitations and discrepancies of transthoracic and transoesophageal echocardiography compared with surgical findings in patients submitted to surgery for complications of infective endocarditis. J Cardiovasc Med (Hagerstown) (2006) 1.38

Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol (2006) 1.38

Controlled analysis of blood pressure sensitivity to sodium intake: interactions with hypertension type. J Hypertens (2003) 1.34

CB(1) signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance. Cell Metab (2010) 1.33

Endothelial cell activation in men with erectile dysfunction without cardiovascular risk factors and overt vascular damage. J Urol (2004) 1.29

Soluble forms of RAGE in internal medicine. Intern Emerg Med (2009) 1.28

Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. Am J Cardiol (2011) 1.26

Retracted Balance between PGD synthase and PGE synthase is a major determinant of atherosclerotic plaque instability in humans. Arterioscler Thromb Vasc Biol (2004) 1.22

Prognostic relevance of masked hypertension in subjects with prehypertension. Am J Hypertens (2008) 1.17

Prognostic value of left ventricular concentric remodeling in uncomplicated mild hypertension. Am J Hypertens (2004) 1.16

Flavonoids, vascular function and cardiovascular protection. Curr Pharm Des (2009) 1.16

Relationship between musculoskeletal symptoms and blood markers of oxidative stress in patients with chronic fatigue syndrome. Neurosci Lett (2003) 1.15

Association between 5-lipoxygenase expression and plaque instability in humans. Arterioscler Thromb Vasc Biol (2005) 1.15

Low-density lipoprotein level reduction by the 3-hydroxy-3-methylglutaryl coenzyme-A inhibitor simvastatin is accompanied by a related reduction of F2-isoprostane formation in hypercholesterolemic subjects: no further effect of vitamin E. Circulation (2002) 1.15

Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. Neoplasia (2009) 1.15

Benefits in cognitive function, blood pressure, and insulin resistance through cocoa flavanol consumption in elderly subjects with mild cognitive impairment: the Cocoa, Cognition, and Aging (CoCoA) study. Hypertension (2012) 1.15

Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing. Clin Cancer Res (2012) 1.15

Fatty acid metabolism in the liver, measured by positron emission tomography, is increased in obese individuals. Gastroenterology (2010) 1.13

Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma. Hypertension (2007) 1.13

A prospective evaluation of iron deficiency anemia in the GI endoscopy setting: role of standard endoscopy, videocapsule endoscopy, and CT-enteroclysis. Gastrointest Endosc (2011) 1.11

PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. J Pathol (2006) 1.11

Epidemiological and economic burden of metabolic syndrome and its consequences in patients with hypertension in Germany, Spain and Italy; a prevalence-based model. BMC Public Health (2010) 1.10

Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation (2002) 1.09

Association between prostaglandin E receptor subtype EP4 overexpression and unstable phenotype in atherosclerotic plaques in human. Arterioscler Thromb Vasc Biol (2005) 1.09